Algorithm for the Treatment of Hyperkalaemia

2

Assess ABCDE

Perform 12 lead ECG or monitor continuous ECG Repeat K⁺ in laboratory Stop all K⁺ containing IV fluids/drugs affecting K⁺ **ECG Changes:** Peaked/tented T waves; wide QRS; long PR interval; diphasic QRS ('sine wave'); flat/loss of P waves; VF/Asystole

| Patient Age | SEVERE | MODERATE | MILD | | |
|----------------------|-----------------------------|------------------------------|--|--|--|
| | ECG changes / | No ECG changes / | No ECG changes / | | |
| | <u>symptomatic</u> | asymptomatic | asymptomatic | | |
| Neonate | $K^+ \ge 7.6 mmol/L$ | K ⁺ 7.1-7.5mmol/L | K ⁺ 6.5-7mmol/L | | |
| > 1 month to < 14yrs | $K^+ \ge 7.1 \text{mmol/L}$ | K ⁺ 6.1-7mmol/L | K ⁺ 5.5-6mmol/L K ⁺ 5.5-6mmol/L | | |
| \geq 14yrs | K ⁺ ≥7.1mmol/L | K ⁺ 6.1-7mmol/L | | | |
| | \Rightarrow STEP 1+2+3 | \Rightarrow STEP 2+3 | \Rightarrow STEP 3 | | |

STEP 1 Assess

STEP 1: Most urgent! Always start with step 1 if severe hyperkalaemia, then continue to steps 2 and 3

| Patient Age | Give IV calcium (stabilises the cardiac membrane to prevent arrhythmias) Can be repeated- see full guideline |
|-------------|--|
| Neonate | Calcium Gluconate 10% 0.5ml/kg over 10 minutes |
| | Give centrally whenever possible, via most distal lumen available |
| | If no central access available, dilute x 5 volume with Sodium Chloride 0.9% |
| >1 month to | Calcium Gluconate 10% 0.5ml/kg over 10 minutes (max 20ml) diluted to 50ml with Sodium |
| <14yrs | Chloride 0.9% |
| ≥14yrs | Calcium Gluconate 10% 20ml over 10 minutes |

STEP 2: Start with step 2 in cases of moderate hyperkalaemia, then continue to step 3

| \sim | Patient Age | Give Salbutamol (moves K ⁺ into cells) | Give Insulin/Glucose (moves K ⁺ into cells) | | | | |
|-----------------|-------------|--|---|--|--|--|--|
| | | Nebs can be rptd- see full guideline | Monitor blood glucose every 30 mins for 6 hours | | | | |
| | Neonate | Give Nebulised Salbutamol as in Step 3 | Add 0.1units/kg soluble insulin (actrapid) to | | | | |
| Ո | >1 month to | or | 1g/kg of glucose. Give over 10 minutes. | | | | |
| | <14yrs | IV Salbutamol 4 microgram/kg/dose | (see Monograph/Appendix C for preparation) | | | | |
| | ≥14yrs | over E minutes, diluted to 2ml with | Add 10 units of soluble Insulin (actrapid) to 50ml | | | | |
| (\mathcal{V}) | | over 5 minutes, diluted to 2mi with | <u>Glucose 50%</u> or 125ml glucose 20% .Give over 5- | | | | |
| | | Sodium Chloride 0.9% | 10 minutes. | | | | |

STEP 3: Start with step 3 in cases of mild hyperkalaemia

| ഹ്) | Patient Age | Nebulised Salbutamol | IV Furosemide | Calcium Resonium |
|---------------|-------------|-----------------------------------|--|--|
| | | (moves K ⁺ into cells) | (increases K ⁺ elimination) | (increases K ⁺ elimination) |
| | Neonate | 2.5mg | 1mg/kg/dose over 5 mins | Rectally 125-250mg/kg/dose four |
| | | | | times a day |
| | >1 month to | 2.5mg for < 10kg | 1mg/kg/dose (max 20 mg) | Oral/rectally 125-250mg/kg/dose |
| | <14yrs | 5mg for ≥ 10kg | over 5 mins | four times day |
| \mathcal{O} | ≥14yrs | 10mg | 20mg over 5 mins | Oral/rectally 15 grams four times |
| | | | | a day |

Monitor

| Use the following table to record and assess response to treatment: | | | | | | | | | |
|---|-------|-------|-------|-------|-------|-------|--------|--------|--------|
| Monitor K [⁺] /gluc | 0min | 15min | 30min | 45min | 60min | 90min | 120min | 4hours | 6hours |
| until K ⁺ is: | Time: | Time: | Time: |
| < 6.5 in those $\leq \frac{1}{12}$ | | | | | | | | | |
| < 5.5 in those > ¹ / ₁₂ | : | : | : | : | : | : | : | : | : |
| K^+ (mmol/L) | | | | | | | | | |
| Glucose (mmol/L) | | | | | | | | | |
| | | | | | | | | | |

Consider Causes of Hyperkalaemia: Renal failure DKA Adrenal insufficiency (e.g. Addison's disease, CAH)

Pseudohyperkalaemia (esp. from haemolysis) Drugs (e.g. K supplements, ACE inhibitors, β-blockers, suxamethonium, trimethoprim, diuretics) Cell lysis (tumour lysis syndrome, rhabdomyolysis, severe burns, trauma)

Hyperkalaemia Management Guideline v1.0

Sept 2019; Review Sept 2021; R Isaac, M Tajik, J Martin